Ping-Chih Hsu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7263820/publications.pdf

Version: 2024-02-01

41	838	623574 14	526166 27
papers	citations	h-index	g-index

41	41	41	1198
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 2019, 20, 3821.	1.8	116
2	YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget, 2017, 8, 114576-114587.	0.8	96
3	YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget, 2016, 7, 51922-51933.	0.8	94
4	Targeting YAP in malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine, 2017, 21, 2663-2676.	1.6	55
5	YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget, 2017, 8, 4096-4109.	0.8	43
6	Inhibition of yesâ€associated protein downâ€regulates PDâ€L1 (CD274) expression in human malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine, 2018, 22, 3139-3148.	1.6	43
7	The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers, 2020, 12, 1361.	1.7	39
8	Response to afatinib in treatment-naÃ¯ve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Review of Anticancer Therapy, 2018, 18, 81-89.	1.1	29
9	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines, 2018, 6, 114.	1.4	28
10	Consolidation treatment of durvalumab after chemoradiation in realâ€world patients with stage III unresectable nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 1541-1549.	0.8	28
11	The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. Oncotarget, 2017, 8, 97602-97612.	0.8	25
12	Inhibition of yesâ€associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. Journal of Cellular and Molecular Medicine, 2018, 22, 3073-3085.	1.6	23
13	Cucurbitacin E inhibits the Yesâ€'associated protein signaling pathway and suppresses brain metastasis of human nonâ€'small cell lung cancer in a murine model. Oncology Reports, 2019, 42, 697-707.	1.2	19
14	Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines, 2021, 9, 1122.	2.1	18
15	Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer, 2021, 21, 859.	1.1	15
16	The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals, 2020, 13, 331.	1.7	14
17	The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. Biomedicines, 2020, 8, 36.	1.4	14
18	Recurrent Pneumonitis Induced by Atezolizumab (Antiâ€"Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis. Journal of Thoracic Oncology, 2018, 13, e227-e230.	0.5	13

#	Article	IF	Citations
19	Downregulation of lumican enhanced mitotic defects and aneuploidy in lung cancer cells. Cell Cycle, 2020, 19, 97-108.	1.3	12
20	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. Cancers, 2022, 14, 977.	1.7	12
21	Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine, 2015, 19, 2385-2396.	1.6	10
22	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers, 2022, 14, 674.	1.7	10
23	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	2.1	9
24	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo <scp>T790M</scp> mutation: A retrospective study of 44 patients. Thoracic Cancer, 2022, 13, 1888-1897.	0.8	8
25	Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). Cancer Treatment and Research Communications, 2016, 9, 48-55.	0.7	7
26	DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma. International Journal of Oncology, 2017, 51, 91-103.	1.4	7
27	Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III nonâ€small cell lung cancer: Results of a singleâ€arm prospective cohort study. Thoracic Cancer, 2019, 10, 1683-1691.	0.8	6
28	The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. Scientific Reports, 2022, 12, 4398.	1.6	6
29	Forced Overexpression of Signal Transducer and Activator of Transcription 3 (STAT3) Activates Yes-Associated Protein (YAP) Expression and Increases the Invasion and Proliferation Abilities of Small Cell Lung Cancer (SCLC) Cells. Biomedicines, 2022, 10, 1704.	1.4	6
30	A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. Oncology and Therapy, 2021, 9, 489-503.	1.0	5
31	Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma. Chemotherapy, 2014, 60, 201-210.	0.8	4
32	Frontâ€line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thoracic Cancer, 2019, 10, 2274-2281.	0.8	4
33	Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. Biomedical Journal, 2016, 39, 121-129.	1.4	3
34	Impaired interferonâ€Î± expression in plasmacytoid dendritic cells in asthma. Immunity, Inflammation and Disease, 2021, 9, 183-195.	1.3	3
35	Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers, 2022, 14, 316.	1.7	3
36	Comparison of Efficacy of 2% Chlorhexidine Gluconateâ€“Alcohol and 10% Povidone-Iodineâ€“Alcohol against Catheter-Related Bloodstream Infections and Bacterial Colonization at Central Venous Catheter Insertion Sites: A Prospective, Single-Center, Open-Label, Crossover Study. Journal of Clinical Medicine, 2022, 11, 2242.	1.0	3

#	Article	IF	Citations
37	Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a caseâ€“control cohort study. International Journal of Dermatology, 2021, 60, 179-184.	0.5	2
38	Topical dicloxacillin solution wash for papulopustular eruptions and purpuric drug eruptions due to epidermal growth factor inhibitors. International Journal of Dermatology, 2021, 60, e278-e281.	0.5	2
39	The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. Frontiers in Oncology, 2021, 11, 671127.	1.3	2
40	Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. Medicina (Lithuania), 2021, 57, 1160.	0.8	1
41	Nuclear p120 catenin is a component of the perichromosomal layer and coordinates sister chromatid segregation during mitosis in lung cancer cells. Cell Death and Disease, 2022, 13, .	2.7	1